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ABSRTACT 
Clonal expansion of Epstein-Barr virus (EBV) infected B-cells occasionally occurs in 
immunocompromized subjects. EBV-infected T/natural killer (NK)-cells proliferate in 
patients with chronic active EBV infection (CAEBV) that is a rare mononucleosis 
syndrome. It is classified into either T-cell type or NK-cell type according to the 
primary target of infection, while the pathogenesis remains unclear. To search the 
clonal origin of EBV-infected T/NK-cells, virus distribution and clonotype were 
assessed by using highly purified cell fractions obtained from 6 patients. Patient 1 had 
a monoclonal proliferation of EBV-infected T-cell receptor Vδ2/Vγ9-expressing cells, 
and carried lower copy number of EBV in αβT-cells. Patients 2 and 3 had a clonal 
expansion of EBV-infected CD4+T-cells, and lower EBV load in CD56+cells. Patients 
4, 5 and 6 had an expansion of CD56+cells with higher EBV load than CD3+cells. 
EBV-terminal repeats were determined as clonal bands in the minor targeted 
populations of 5 patients. The size of terminal repeats indicated the same clonotype in 
minor subsets as in major subsets of 4 patients. However, EBV was not detected in 
bone marrow-derived lineage negative CD34+cells of patients. These results suggested 
that EBV could infect T/NK-cells at differentiation stage, but spared bone marrow 
CD34+hematopoietic stem cells in CAEBV patients. 
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INTRODUCTION 
More than 90% adults are infected with Epstein-Barr virus (EBV), and the infection 
persists for life. The primary infection often causes acute infectious mononucleosis 
(IM) in adolescents or young adults. The γ herpes virus enters CD21+B cells, and 
establishes latent infection in the memory B-cell pools evading immune elimination by 
EBV-specific cytotoxic T-cells.1 EBV-infected B-cell lymphoproliferative disease 
(LPD) occurs in immunocompromized patients. Recently, novel EBV-driven T/natural 
killer (NK)-cell LPD has been identified in non-immunocompromised hosts such as 
chronic active EBV infection (CAEBV) and EBV-associated hemophagocytic 
lymphohistiocytosis (HLH).2,3 CAEBV is a rare mononucleosis syndrome typified by 
high circulating levels of EBV DNA and recurrent IM-like symptoms along with 
coronary artery lesions, chorioretinitis, and brain involvement.4 It was first described 
as a progressive EBV infection targeting B-cells, but most cases are reported from Asia 
as EBV-infected T/NK-cell LPD. The Asian type CAEBV is classified into T-cell type 
or NK-cell type according to the target of infection.5-7 The NK-cell type might be 
linked with hypersensitivity to mosquito bite (HMB) and slow progression. However, 
affected patients with either type result in fetal demise without allogeneic stem cell 
transplantation (SCT).8,9 CD8+T cells are exclusively targeted in EBV-HLH patients, 
while the virus spreads over T/NK-cell subsets in CAEBV patients. The cell-type 
specific infection does not stipulate the transformation or tissue infiltration. Despite the 
increasing number of reports,10 the cause of T/NK-cell infection remains unclear. 
 The episome of EBV DNA has a highly variable reiteration of terminal repeat 
(TR) sequences that are joined by random recombination upon circularization of the 
linear genome at entry into cells. As the TR number is inherent in a round of EBV 
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reactivation and reinfection, the diversification denotes the latently infected cell clones. 
Nonetheless, cell purity and blotting sensitivity have hampered the precise analysis of 
CAEBV T/NK-cells. EBV-producing T/NK-cell lines established from patients do not 
represent the in vivo clonal nature. 
In the present study, EBV load and clonality of T/NK-cell subsets were analyzed in 
CAEBV patients by using the high-accuracy cell sorting. EBV DNA was detected in 
the major targeted subsets as well as in the other subsets with the evidence of 
clonotypic infection. These results first implied the infection of T/NK-cell precursors. 
Whereas, bone marrow (BM)-derived CD34+ cells, supposed to include common 
lymphoid progenitors, were not involved in the infection. The pathogenesis of CAEBV 
was discussed with special reference to the cellular origin of EBV infection. 
 
MATERIALS and METHODS 
Patients  
Six Japanese patients treated in Kyushu University Hospital between 2002 and 2008, 
were recruited. All fulfilled the diagnostic criteia.11 Clinical profiles are shown in 
Table 1. Median age at the onset of illness was 3.5 years (range: 1~8). The unique 
symptoms included HMB (n=4), hydroa vacciniforme (n=4), and coronary artery 
lesion (n=1). Three patients had abnormal patterns of anti EBV-antibodies (Abs). Five 
had increased number of activated T-cells and/or high CD4/CD8 ratio. Primary target 
was T-cell in 3 and NK-cell in 3 patients. Clonality was screened for peripheral blood 
(PB) mononuclear cells (MNCs) by EBV-TR and immunoglobulin (Ig)/T-cell receptor 
(TCR) genes. No patients received cytotoxic agents at the time of study. Controls 
included EBV-seropositive subjects or patients with immune thrombocytopenia. 
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Antibodies, cell staining, and sorting 
Mononuclear cells were separated by centrifugation using separation medium (Cappel, 
Aurora, OH). Each cell fraction was positively selected by immunomagnetic beads 
with Vario-MACS columns (Miltenyi Biotec, Bergisch Gladbach, Germany) after the 
staining with monoclonal Abs (mAbs) against CD3, CD4, CD8 and CD56. TCR 
Vδ2+cells and TCRαβ+cells were procured by using MACS anti-FITC or anti-PE 
microbeads (Miltenyi Biotec) after the staining with FITC-conjugated anti-Vδ2 mAb 
(Immunotech/Beckman Coulter, Marseille, France), or PE-conjugated TCRαβ mAb. 
CD56+cells were positively collected using Lymphocyte Separation column (Miltenyi 
Biotec, Bergisch Gladbach, Germany), after the depletion of CD3+cells by Lymphocyte 
Depleting column. The procedures yielded cell samples with more than 97% of purity, 
which was determined by the flow cytometry using EPICS XL (Immunotech Coulter 
[IC], Miami, FL). To raise the maximum purity (>99.9%) of CD3+cells, Vδ2+cells, 
TCRαβ+cells, and CD34+cells, all sorting and analyses were performed on FACS Aria 
(BD Biosciences, Oxnald, PA, USA). CD3+cells, Vδ2+cells, and TCRαβ+cells were 
positively sorted after staining with each FITC-conjugated mAbs. BM CD34+cells 
were sorted as follows; CD34+cells were enriched from BM cells by using the Indirect 
CD34 MicroBead Kit (Miltenyi Biotec) as described previously.12 For analyses and 
sorting, cell samples were stained with Cy5-PE- or PC5-conjugated lineage mixture, 
including Cy5-PE- or PC5-conjugated anti-CD3, CD4, CD8, CD10, CD20, CD11b, 
CD14, GPA, FITC-conjugated anti-CD3, CD4 or Vδ2, PE-conjugated anti-Vαβ, CD16, 
or CD56, allophycocyanin (APC)-conjugated anti-CD34, and nonviable cells were 
excluded by propidium iodide (PI) staining. CD34+cells were isolated from BM cells 
by FACS Aria. Appropriate isotype-matched control mAbs were used to determine the 
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background staining level in each channel. To avoid any contamination, the second 
round of sorting was performed routinely with the same sorting gates as the first round. 
FACS data were analyzed with FlowJo software (Tree Star, Inc.). The re-analyses 
warranted the consistent purity of > 99.9% procured cells (Supplementary figure 1). 
DNA extraction and real-time PCR for EBV-DNA 
High molecular DNA was extracted from cell samples. DNA was used for PCR and 
Southern blotting. The real-time PCR for EBV DNA was performed according to the 
established method.4,6 Briefly, TaqMan probe was labeled with the reporter dye 
molecule at the 5' end, and with the quencher flour at the 3' end via a linker arm 
nucleotide. Gene dosages were analyzed by ABI PRISM 7700 (PE Biosystems, Foster 
City, CA). DNA was mixed with TaqMan Universal PCR Master Mix (PE Biosystems), 
primers, and TaqMan probe. PCR conditions were 50 oC for 2 min and 95 oC for 10 
min, followed by 50 cycles at 95 oC for 15 sec, and 60 oC for 1 min. Healthy persons 
with past EBV infection show <200 copies/ml and <40 copies/μgDNA in PB and 
MNCs, respectively. 
Southern blotting probed with EBV-tandem repeats (TR) or TCR/Ig genes 
Southern blotting was performed as the established method.2,13 Briefly, 5μg of high 
molecular weight DNA were digested with EcoRI and/or BamHI. The digested DNA 
was electrophoresed on 0.9% agarose gel and transferred to Byodine-B, which was 
hybridized with a 32P-labeled probe. Clonality of lymphocytes was assessed probed 
with a 5.2-kb BamHI-EcoRI fragment containing the TR sequence of the EBV genome, 
and/or TCR/immunoglobulin (Ig) gene probes of Cβ1, Jβ1, Jβ2, Jγ, and JH. Normal 
control DNA was extracted from MNC of healthy EBV-seropositive adults. 
Gene analysis of γδT-cells 
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Genomic DNA was extracted from highly purified PB panTCRγδ positive PB MNCs 
by the conventional methods. Direct sequencing of PCR product of N-regions was 
completed for TCRδ-gene and TCRγ-gene. The exon and exon–intron boundary 
regions of each gene were amplified by PCR, and the products were then subjected to 
direct sequencing using 3130xl Genetic Analyzer (Life Technologies Corp., CA, USA). 
Immunohistology 
BM clot samples fixed in buffered formalin and embedded in paraffin wax, were 
immunostained with Abs against CD3, CD4, CD8, CD56, latent membrane protein 
(LMP1) and EBNA-2 (Dako, Copenhagen, Denmark). For in situ hybridization (ISH) 
to detect EBV-RNA, the samples was hybridized with an oligo-probe (EBER-1 region) 
and a sense probe (negative control), and then was labeled with digoxigenin as our 
methods.14 Briefly, after de-waxing, dehydration and proteinase-K digestion, the 
sections were hybridized overnight in a solution of 50% formamide containing 5 ng 
DIG-labeled probes. After washing, detection was accomplished using an 
avidin-alkaline-phosphatase conjugate. 
 
RESULTS 
Target cells and clinical expression 
T-cell type  Patient (Pt) 1 presented fever and skin eruption. CD4-CD8-γδ T cells 
increased to 30 % of PB MNC, which expressed Vδ2/Vγ9 (Figure 1). PCR products 
amplified by Vδ2 or Vγ9 primer indicated clonal proliferation of Vδ2/Vγ9 T-cells. 
Sequencing of Vγ9-JγP1 junctional transcripts revealed an N-region sequence (Table 
2). Vδ2+cells and TCRαβ+cells had 4×105 and 4×103 copies EBV/μgDNA, respectively. 
Screening blotting of MNC showed a single EBV-TR and TCRγ gene rearrangement. 
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The clonal expansion of EBV-infected Vδ2/Vγ9 T-cells has continued for 6 years. Pt 2 
suffered hydroa vacciniforme. CD3+cells, CD8+cells and CD56+cells carried 2×105, 
5x103 and 9×103 copies/μgDNA, respectively. Screening blotting indicated diclonal 
expansion of EBV+CD4+T-cells. At 25 years of age, she underwent a sibling donor 
SCT because of cutaneous lymphoma with EBER1+ CD4+T-cells or CD56+cells. She 
attained EBV-free remission, but died of graft-versus-host disease. Pt 3 had fever and 
hepatitis. CD4+cells, CD8+cells and CD56+cells had 3×104, 90 and <40 copies/μgDNA, 
respectively. He attained remission after an HLA-matched sibling donor BMT. 
NK-cell type  Pt 4 showed aggressive course with cardiac and enteral involvement. 
EBV-infected CD56+cells infiltrated vesicular HMB lesions. CD4+cells, CD8+cells and 
CD56+cells carried 2×103, 1×103, and 4×105 copies/μgDNA, respectively. Screening of 
MNC showed diclonal TR bands. She attained EBV-free remission after cord blood 
transplantation. Pt 5 had fever and HMB. CD3+cells and CD56+cells carried 3×104 and 
8×105 copies/μgDNA, respectively. Skin infiltrations with EBER1+ CD4+cells subsided 
by low dose prednisolone. Pt 6 showed fever and HMB. CD4+cells, CD8+cells and 
CD56+cells had 8×103, 4×104, and 4×105 copies/μgDNA, respectively. 
Clonality of EBV-infected subsets 
The clonotype of EBV-infected subsets were assessed by Southern blotting with TR 
probe for highly purified cell fractions. The blotting sensitivity was estimated to detect 
more than 0.5% contamination of EBV-infected cells by the add-back experiments 
(Supplementary figure 2). As shown in Figure 2, TCRαβ cell fraction (>99.9%) 
showed the same sized single band as Vδ2+ cells in Pt 1 after either EcoRI or BamHI 
digestion (Figure 2). Pt 2 and Pt 3 having high EBV load in CD4+ T-cells showed a 
single TR band in CD56+cells and no detectable band in CD8+ T-cells, respectively. 
Leukemia 
Original article 
 10
 
The TR size in CD56+cells of Pt 2 was same as one of diclonal bands in CD3+ T-cells. 
The clonotype in highly purified T-cells was assessed in NK-cell type CAEBV. 
Clonal TR bands were detected in CD3+cells (>99.5%) in all 3 patients. The diclonal 
bands and monoclonal band in CD3+cells of Pt 4 and Pt 5 were in the same size as 
those in the CD56+cells, respectively. On the other hand, in Pt 6, CD3+cells showed a 
distinct monoclonal band in larger size than CD56+cells (Figure 2). The screening of 
MNC from Pt 6 showed the same sized TR band as CD56+ cells. 
EBV load in BM CD34+ cells 
To further assess the cellular origin of EBV-infection, the virus load was re-quantified 
using highly purified cells. EBV DNA was undetectable in BM derived lin-CD34+ cells 
of 5 patients studied, and seropositive controls (Figure 3). Immunohistochemical 
staining and/or in situ hybridization of BM clot samples revealed no detectable CD34+ 
cells positive for LMP1, EBNA or EBER (Figure 4). 
 
DISCUSSION 
Clonal expansion of EBV-infected T/NK-cells was determined not only in the 
major targeted subsets but also in the less infected subsets of CAEBV patients. The 
clonotype of EBV in the minor targeted cells notably coincided with that in the major 
EBV-infected T/NK-cell fractions. On the other hand, BM-derived CD34+ cells did not 
carry EBV DNA. These suggested that EBV infection could occur at differentiation 
stages of lymphocytes and then clonally expand to diverse subsets of T/NK-cells, but 
not involve CD34+ hematopoietic stem cells in CAEBV patients. 
It has been controversial whether CAEBV is defined as chronic infection or clonal 
disorder. Diverse subsets of T-cells and/or NK-cells of CAEBV patients carried EBV 
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DNA as expected. T-cell and NK-cell lines shedding EBV have been established from 
CAEBV patients.15,16 EBER1+ T-cells and NK-cells are found in the tonsils of patients 
with acute IM.17 EBV could infect T/NK-cells during the primary infection. If the 
excessive viral load raises the chance of ectopic infection, the diverse infection in 
T/NK-cell subsets might be explained by the frequent reactivation and reinfection of 
lytic virus during the prolonged course of CAEBV. Reactive T-cells oligoclonally 
expand in CD8+ but not CD4+ subsets of patients with acute IM.18 In the current study, 
EBV-infected T/NK-cells clonally proliferated in the major targeted populations 
(non-CD8+ T-cells) as well as other subsets of CAEBV patients. The primary targeted 
cells (Vδ2 in Pt 1, NK-cells in Pt 2 and Pt 3) and other minor subsets (αβT cells in Pt 1, 
T-cells in Pt 4 and Pt 6) shared the same sized TR. PB γδT-cells of healthy human 
consist entirely of polyclonal Vδ2/Vγ9 T-cells, while those of Pt 1 originate from a 
single EBV-carrying Vδ2/Vγ9 clone. Toyobe et al.19 reported a CAEBV patient who 
had biclonal expansion of Vβ7+ and Vβ9+ cells in PB CD4+ T-cells. These T-cell clones 
were primarily targeted by EBV, and the strain was indistinguishable from each other 
by genotype analyses. Endo et al.20 analyzed the clonotype of EBV in 2 CAEBV 
patients who had biphenotypic expansions of CD4+ and CD8+ T cells. Both T-cell 
subsets carried the same TR sized clone of EBV with hypermethylated status in the Cp 
region. Germinal center B-cells retaining latent EBV could be the source of B-cell 
LPD.21 In this line, the diverse T/NK-cell infection in CAEBV patients might not stem 
from the spread of lytic infection but the differentiation and expansion of EBV-infected 
T/NK-cells retaining the latent episome. Alternative explanation of the clonotypic virus 
is that EBV gene was integrated into the host genome.22 Proliferating EBV-infected 
T/NK-cells of CAEBV patients lack malignant morphology. EBV latent genes are 
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expressed in heterogeneous and restricted patterns in the EBV-infected T/NK-cells of 
CAEBV patients.23 The integration of a specific site of EBV genome is unlikely in 
CAEBV T/NK-cells. Taken together, it may raise the possibility that EBV infection 
occurs at an early stage of differentiation, and the clonotypic EBV-infected T/NK-cells 
enter the circulating lymphocytes. Multiple EBV strains are differently associated with 
EBV-associated tumors in a single host.24 Further study on the site specific clonality 
might provide a clue to the pathophysiology of CAEBV. 
The major concern is how clonal EBV-infected T/NK-cells are allowed in patients. 
The etiological analogy was inferred between CAEBV and X-linked LPD, while EBV+ 
B-cell LPD arises in the latter. Only a Caucasian patient with the B-cell type CAEBV 
had defective cytotoxicity due to PRF1 mutations.25 However, no genetic defects have 
been identified in T/NK-cell type CAEBV or EBV-HLH.26,27 Cytotoxic defect has been 
implicated in CAEBV patients,28 though EBV-infected T/NK-cells may have altered 
cytotoxicity. No familial occurrence was determined in the cases with T/NK-cell type 
CAEBV reported in Asians and Latin Americans. To the best of our knowledge, in two 
Japanese pairs of identical twins, one suffered from CAEBV but each counterpart was 
healthy carrier. The end-to-end length of fused TRs may itself drive clonal selection 
consequent to the opposing growth advantages and disadvantages of LMP1.29 The 
dynamics of primary infection may provide a clue to the evolution of CAEBV. 
CAEBV patients die without successful allogeneic SCT, which eradicates 
EBV-infected hematopoietic cells and reconstitutes the normal EBV-specific immunity. 
Based on the clonotypic EBV in CAEBV patients, we hypothesized that CD34+ 
hematopoietic stem cells might be targeted by the infection. HIV-1-infected CD34+ 
hematopoietic stem cells have been detected in a subpopulation of HIV-positive 
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patients, ranging from 14 to 36%.30 HTLV-1 or HHV8 infects CD34+ hematopoietic 
stem cells,31 although those cells appeared not to be the major reservoir in carriers. The 
current results first indicated that BM CD34+ cells were not a niche of EBV infection 
in CAEBV patients. The primitive hematopoietic stem cells are resistant to HIV-1 
infection, although once these cells begin to differentiate and become committed 
hematopoietic stem cells they become increasingly susceptible to HIV-1 infection and 
permissive to viral gene expression and infectious virus production.32 EBV might 
target CD34 negative T-cell progenitors prior to the differentiation into αβ T cells and 
γδ T cells. Quiescent hematopoietic stem cells are resistant to in vitro infection of 
pathogens. Dormant CD34+ cells in BM might be protected from infection, or 
promptly eliminated after infection. CAEBV may be a clonal disease of EBV-infected 
lymphoid progenitor cells, arising from cytotoxic defect of unknown cause. It explains 
the rationale of the allogeneic SCT that is necessary for complete recovery of CAEBV 
patients. Further study on the origin of EBV-infected T/NK-cells may shed some lights 
not only on the relationship between infection and clonal disease, but also on the 
therapeutic target of EBV-associated T/NK-cell LPD/lymphoma. 
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FIGURE LEGENDS 
Figure 1.  Representative flow cytometry for lymphocytes of Patient 1. TCRγδ cells 
increased to ~30% of peripheral blood lymphocytes, exclusively expressing Vγ9/Vδ2 
but negligible expression of HLA-DR. Vγ4- and Vδ3-expressing cells were <1% of 
lymphocytes. More than 99% of Vδ2+ lymphocytes were CD4-CD8- T cells. 
Figure 2.  Southern blotting analysis of high molecular DNA obtained from highly 
purified cell fractions (>99.5%) probed with the EBV-terminal repeated (TR) sequence. 
EcoRI (E) or BamHI (B)-digested DNA was electrophoresed (2~5μg/lane) and 
hybridized with a 32P-labeled 5.2-kb BamHI-EcoRI fragment containing the TR repeat 
sequences. The blotting sensitivity was confirmed to detect >0.5% contamination of 
EBV-infected cells. Arrow, a clonal band. * non-specific band in each digestion. NC: 
normal control of healthy human lymphocytes, PC: positive control of Raji cell lines. 
Figure 3.  Quantification of EBV DNA in highly purified cell fractions (>99.9%) 
obtained from CAEBV patients assessed by real-time PCR. High molecular DNA was 
extracted from Vδ2, αβT, CD4, CD3, and CD56-expressing cells fractionated from 
peripheral blood, and CD34+ cells (hatched bar) obtained from bone marrow cells. 
Solid bars represent the major infected subsets with high EBV load (black bar), and 
the minor infected subsets with low EBV load (gray bar). 
Figure 4.  Immunohistochemical staining of bone marrow (BM) cells obtained from 
Patient 5 and Patient 6. BM clot samples were stained with anti-CD34 antibody using 
fuchsin as a chromogen for visualization of alkaline phosphatase activity (positive: red 
cytosol, open arrow), and were then employed for in situ hybridization of EBER1 
using diaminobenzidine as a chromogen of peroxidase (positive: brown nucleus, closed 
arrow). There were no double positive cells for CD34 and EBER1 in BM cells. 
Table 1. Clinical profiles of patients with chronic active EBV infection 
------------------------------------------------------------------------------------------------------------------------ 
Patient   1 2 3 4 5 6 
------------------------------------------------------------------------------------------------------------------------ 
Sex   f f m f m m  
Age (yrs) at onset, at the study 6, 7 8, 25 2, 5 4, 4 1, 10 3, 8 
Involvement         
CAL  no no no yes no no  
Enteral  no no no yes no no 
HMB  no yes no yes yes yes  
HV  yes yes no no yes yes  
Anti EBV-Abs         
VCA-IgG  160 640 1280 640 160 160  
-IgM  <10 <10 <10 <10 <10 <10  
-IgA  <10 40 20 <10 <10 <10  
EADR-IgG <10 160 640 40 10 10  
-IgA  na na <10 160 <10 <10  
EBNA  40 10 40 40 80 80  
EBV-DNA1)  PB/MNC 100/106 300/104 600/na 3000/na 300/105 2000/na  
Major targeted subsets γδT CD4 CD4 CD56 CD56 CD56  
CD3/CD19/CD56 (%) 70/28/2 75/18/7 69/24/7 82/5/13 47/17/36 58/15/27  
CD3+HLA-DR+ (%)  14.4 21.5 15.8 14.2 0.6 5.9  
CD4/CD8   1.6 0.8 5.3 2.0 3.3 2.9  
Clonality2)  EBV-TR  M D M D M M  
TCR  R R na G G G  
Outcome   AOD Death ADF ADF AOD AOD  
    post-SCT post-SCT post-SCT  
------------------------------------------------------------------------------------------------------------------------ 
1) Each value means the copy number of EBV DNA (PB: /ml, MNC: /μgDNA). 
2) Clonality was screened by Southern blotting for PB-MNC derived DNA probed with EBV-TR, 
TCR and Ig genes. There was no evidence of clonally proliferating B cells. CAEBV: chronic active 
Epstein-Barr virus infection, EBV: Epstein-Barr virus, CAL: coronary artery lesion, CNS: central 
nervous system, HMB: hypersensitivity to mosquito bite, HV: hydroa vacciniforme, VCA: viral 
capsid antigen, EBNA: EBV nuclear antigen, PB: peripheral blood, MNC: mononuclear cells, TR: 
terminal repeat, TCR: T-cell receptor, M: monoclonal, D: diclonal, R: rearrangement, G: germ line, 
AOD: alive on disease, ADF: alive on disease free state, SCT stem cell transplantation 
Table 2
Table 2. Nucleotide Sequence of V9-JP1Junctional Transcripts Expressed by T-Cells
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
V9 N region JP1
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Germline ATT CCG TCA GCC ****TAC TGT GCC TTG TGG GAG GTG ACC ACT GGT TGG ATC
V9 primer JT3 primer
Pt TGT GCC TTG TGG GAG GTG CAG ACC ACT GGT TGG TTC AAG ATA TTT GCT GAA GGG ACT AAG
C A L W E V Q T T G W
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
The germline sequences of the 3' end of V9, N region, and the 5' end of JP1 gene segments are at the top.




